Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 28;5(2):169-176.
doi: 10.14218/JCTH.2016.00071. Epub 2017 Mar 30.

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Jun Yin  1 , Wen-Tao Bo  2 , Jian Sun  3 , Xiao Xiang  4 , Jin-Yi Lang  1 , Jian-Hong Zhong  4 , Le-Qun Li  4
Affiliations
Review

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Jun Yin et al. J Clin Transl Hepatol. .

Abstract

Portal vein tumor thrombosis (PVTT) is an intractable condition but common phenomenon in hepatocellular carcinoma (HCC). HCC patients with PVTT may have worse liver function, a higher chance of comorbidity related to portal hypertension, lower tolerance to treatment and poorer prognoses. In Western guidelines, patients are offered palliative treatment with sorafenib or other systemic agents because HCC with PVTT is grouped together with metastatic HCC during the planning of its management. In recent years, various treatment options have become available for patients with HCC and PVTT. Therapy has also shifted toward evidence-based treatment. However, policies for the management of HCC with PVTT have not been established. This comprehensive literature review aims to present current and available management options for patients with HCC and PVTT. Evidence is mainly based on studies published after 2010.

Keywords: Hepatic resection; Hepatocellular carcinoma; Portal vein tumor thrombosis; Transarterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests related to this publication.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. . - DOI - PubMed
    1. Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol. 2016;22:7289–7300. . - DOI - PMC - PubMed
    1. Zhong JH, You XM, Ma L, Xiang BD, Wu FX, Peng NF, et al. Tumor stage and primary treatment selection among patients with hepatocellular carcinoma from 2003 to 2013. Chinese Journal of Oncology Prevention and Treatment. 2015;7:403–407.
    1. Xiang X, Zhong JH, Wang YY, You XM, Ma L, Xiang BD, et al. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clin Transl Oncol. 2017 . - DOI - PubMed
    1. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103–109. . - DOI - PMC - PubMed

LinkOut - more resources